Separate terms with OR to return results that match either term.
 
Clear All

602 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class (Ascending) Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA ixazomib Ninlaro 3 mg Chemotherapy Proteasome Inhibitor 20S Yes 2015 In Use
NA ixazomib Ninlaro 4 mg Chemotherapy Proteasome Inhibitor 20S Yes 2015 In Use
J9041 Bortezomib Velcade 0.1 mg Chemotherapy Proteasome Inhibitor 26S No 2003 Jan. 1, 2005 In Use
S0115 Bortezomib Velcade 3.5 mg Chemotherapy Proteasome Inhibitor 26S No 2003 Jan. 1, 2004 Dec. 31, 2004 No Longer Used
NA Dutasteride Avodart 0.5mg Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Yes 2002 In Use
NA Finasteride Proscar 5mg Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Yes 1992 In Use
J8655 Netupitant/palonostron Akynzeo 300mg/0.5 mg Ancillary Therapy Antiemetic 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 Yes 2014 Jan. 1, 2016 In Use
Q9978 Netupitant/palonostron Akynzeo 300mg/0.5 mg Ancillary Therapy Antiemetic 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 Yes 2014 July 1, 2015 Dec. 31, 2015 No Longer Used
C9448 Netupitant/palonostron Akynzeo 300mg/0.5 mg Ancillary Therapy Antiemetic 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 Yes 2014 April 1, 2015 June 30, 2015 No Longer Used
S0174 Dolasetron Mesylate Anzemet 50 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1997 Jan. 1, 2002 In Use
Q0180 Dolasetron Mesylate Anzemet 100 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1997 April 1, 1998 In Use
J1260 Dolasetron Mesylate Anzemet 10 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 1997 Jan. 1, 2000 In Use
J1627 Granisetron Hydrochloride Extended Release Granisol [DSC], Sancuso, Sustol, Kytril 0.1 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 2016 Jan. 1, 2018 In Use
J1626 Granisetron Hydrochloride Granisol [DSC], Sancuso, Sustol, Kytril 100 mcg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 1993 Jan. 1, 2009 In Use
Q0166 Granisetron Hydrochloride Granisol [DSC], Sancuso, Sustol, Kytril 1 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1993 Jan. 1, 2009 In Use
S0091 Granisetron Hydrochloride Granisol [DSC], Sancuso, Sustol, Kytril 1 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1993 Jan. 1, 2002 In Use
J2405 Ondansetron Zofran, Zofran ODT, Zuplenz 1 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 1991 Jan. 1, 1993 In Use
Q0179 Ondansetron Zofran, Zofran ODT, Zuplenz 8 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1991 April 1, 1998 Dec. 31, 2011 No Longer Used
Q0162 Ondansetron with active chemotherapy treatment adminstration Zofran, Zofran ODT, Zuplenz 1 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1991 Jan. 1, 2012 In Use
S0181 Ondansetron Zofran, Zofran ODT, Zuplenz 4 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1991 Jan. 1, 2002 Dec. 31, 2011 No Longer Used
S0119 Ondansetron Zofran, Zofran ODT, Zuplenz 4 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1991 Jan. 1, 2012 In Use
C9210 Palonosetron Aloxi 25 mcg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 2003 Jan. 1, 2004 Dec. 31, 2004 No Longer Used
J2469 Palonosetron Aloxi 25 mcg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 2003 Jan. 1, 2005 In Use
NA Alectinib Alecensa 150 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2015 In Use
NA Brigatinib Alunbrig 30 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2017 In Use

Found 602 results in 2 millisecondsExport these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.